Lycopene modulates growth and survival associated genes in prostate cancer

Journal of Nutritional Biochemistry

Volumn 24, Issue 10, 2013, Pages 1724-1734

  Rafi, Mohamed M ^a   Kanakasabai, Saravanan ^b   Reyes, Marynell D ^a   Bright, John J ^b,c  

^a RUTGERS UNIVERSITY   (United States)

^b METHODIST RESEARCH INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer prevention; Carotenoids; Lycopene; PC 3 cells; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CIGLITAZONE; DOXORUBICIN; LYCOPENE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROSTAGLANDIN J2; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; TOMATO;

LYCOPERSICON ESCULENTUM;

B-CELL LYMPHOMA-2; B-CELL LYMPHOMA-2 LIKE 1; BCL-2; BCL2L1; BRCA1; BREAST CANCER 1; CANCER PREVENTION; CAROTENOIDS; CDK-7; CDK-9; CYCLIN DEPENDENT KINASE-7; CYCLIN DEPENDENT KINASE-9; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; FBS; FETAL BOVINE SERUM; IGF1R; INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR; LYCOPENE; PBS; PC-3 CELLS; PHOSPHATE-BUFFERED SALINE; PROSTATE CANCER; REAL-TIME PCR; REAL-TIME POLYMERASE CHAIN REACTION; TGFΒ-2; TRANSFORMING GROWTH FACTOR BETA-2;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAROTENOIDS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; HUMANS; MALE; NECROSIS; PPAR GAMMA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883799347     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.03.001     Document Type: Article

References (47)

1. Krinsky N.I., Johnson E.J. Carotenoid actions and their relation to health and disease. Mol Aspects Med 2005, 26:459-516.
2. Rao A.V., Rao L.G. Carotenoids and human health. Pharmacol Res 2007, 55:207-216.
3. Eid S.Y., El-Readi M.Z., Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine 2012, 19:977-987.
4. Kong K.W., Khoo H.E., Prasad K.N., Ismail A., Tan C.P., Rajab N.F. Revealing the power of the natural red pigment lycopene. Molecules 2010, 15:959-987.
5. Bhuvaneswari V., Nagini S. Lycopene: a review of its potential as an anticancer agent. Curr Med Chem Anticancer Agents 2005, 5:627-635.
6. Ilic D., Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 2012, 72:269-276.
7. McEneny J, Wade L, Young IS, Masson L, Duthie G, et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J Nutr Biochem [e-pub 2012].
8. Nagal S, Kaur C, Choudhary H, Singh J, Bhushan Singh B, et al. Lycopene content, antioxidant capacity and colour attributes of selected watermelon (Citrullus lanatus (Thunb.) Mansfeld) cultivars grown in India. Int J Food Sci Nutr [epub 2012].
9. La Vecchia C., Negri E., Pelucchi C., Franceschi S. Dietary folate and colorectal cancer. Int J Cancer 2002, 102:545-547.
10. Holick C.N., Michaud D.S., Stolzenberg-Solomon R., Mayne S.T., Pietinen P., et al. Dietary carotenoids, serum beta-carotene, and retinol and risk of lung cancer in the alpha-tocopherol, beta-carotene cohort study. Am J Epidemiol 2002, 156:536-547.
11. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
12. Pal RP, Maitra NU, Mellon JK, Khan MA. Defining prostate cancer risk before prostate biopsy. Urol Oncol [epub 2012].
13. Giovannucci E., Rimm E.B., Liu Y., Stampfer M.J., Willett W.C. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002, 94:391-398.
14. Mohanty N.K., Saxena S., Singh U.P., Goyal N.K., Arora R.P. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol 2005, 23:383-385.
15. Chakrabarti R., Robles L.D., Gibson J., Muroski M. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet 2002, 139:115-125.
16. Chen L., Stacewicz-Sapuntzakis M., Duncan C., Sharifi R., Ghosh L., et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001, 93:1872-1879.
17. Tang L., Jin T., Zeng X., Wang J.S. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 2005, 135:287-290.
18. Rafi M.M., Yadav P.N., Reyes M. Lycopene inhibits LPS-induced proinflammatory mediator inducible nitric oxide synthase in mouse macrophage cells. J Food Sci 2007, 72:S069-S074.
19. Horwitz S.B., Parness J., Schiff P.B., Manfredi J.J. Taxol: a new probe for studying the structure and function of microtubules. Cold Spring Harb Symp Quant Biol 1982, 46(Pt 1):219-226.
20. De Brabander M., Geuens G., Nuydens R., Willebrords R., De Mey J. Microtubule stability and assembly in living cells: the influence of metabolic inhibitors, taxol and pH. Cold Spring Harb Symp Quant Biol 1982, 46(Pt 1):227-240.
21. Roth B.J., Yeap B.Y., Wilding G., Kasimis B., McLeod D., et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993, 72:2457-2460.
22. Tsakalozou E., Eckman A.M., Bae Y. Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int 2012, 2012:832059.
23. Tehranian N., Sepehri H., Mehdipour P., Biramijamal F., Hossein-Nezhad A., et al. Combination effect of PectaSol and Doxorubicin on viability, cell cycle arrest and apoptosis in DU-145 and LNCaP prostate cancer cell lines. Cell Biol Int 2012, 36:601-610.
24. Taverna P., Catapano C.V., Citti L., Bonfanti M., D'Incalci M. Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 1992, 3:401-405.
25. Zhang W.B., Wang Z., Shu F., Jin Y.H., Liu H.Y., et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 2010, 285:40461-40471.
26. Sato A., Sunayama J., Matsuda K., Seino S., Suzuki K., et al. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells 2011, 29:1942-1951.
27. Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
28. Pestereva E., Kanakasabai S., Bright J.J. PPARgamma agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells. Br J Cancer 2012, 106:1702-1712.
29. Chearwae W., Bright J.J. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 2008, 99:2044-2053.
30. Mansour M., Schwartz D., Judd R., Akingbemi B., Braden T., et al. Thiazolidinediones/PPARgamma agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol 2011, 38:537-546.
31. Xu Y., Iyengar S., Roberts R.L., Shappell S.B., Peehl D.M. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol 2003, 196:131-143.
32. Ban J.O., Oh J.H., Son S.M., Won D., Song H.S., et al. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression. Cancer Biol Ther 2011, 12:288-296.
33. Yang C.M., Lu Y.L., Chen H.Y., Hu M.L. Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway. J Nutr Biochem 2012, 23:1155-1162.
34. Yang C.M., Lu I.H., Chen H.Y., Hu M.L. Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARgamma-LXRalpha-ABCA1 pathway. J Nutr Biochem 2012, 23:8-17.
35. Yang C.M., Yen Y.T., Huang C.S., Hu M.L. Growth inhibitory efficacy of lycopene and beta-carotene against androgen-independent prostate tumor cells xenografted in nude mice. Mol Nutr Food Res 2011, 55:606-612.
36. Burgess L.C., Rice E., Fischer T., Seekins J.R., Burgess T.P., et al. Lycopene has limited effect on cell proliferation in only two of seven human cell lines (both cancerous and noncancerous) in an in vitro system with doses across the physiological range. Toxicol In Vitro 2008, 22:1297-1300.
37. Stearns M.E., Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992, 52:3776-3781.
38. Tian Y., Nan Y., Han L., Zhang A., Wang G., et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. Int J Oncol 2012, 40:1105-1112.
39. Calvo A., Gonzalez-Moreno O., Yoon C.Y., Huh J.I., Desai K., et al. Prostate cancer and the genomic revolution: advances using microarray analyses. Mutat Res 2005, 576:66-79.
40. Hernes E., Fossa S.D., Berner A., Otnes B., Nesland J.M. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004, 90:449-454.
41. Shah R.B., Ghosh D., Elder J.T. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate 2006, 66:1437-1444.
42. Blanchere M., Saunier E., Mestayer C., Broshuis M., Mowszowicz I. Alterations of expression and regulation of transforming growth factor beta in human cancer prostate cell lines. J Steroid Biochem Mol Biol 2002, 82:297-304.
43. Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002, 62:2942-2950.
44. Loughran G., Huigsloot M., Kiely P.A., Smith L.M., Floyd S., et al. Gene expression profiles in cells transformed by overexpression of the IGF-I receptor. Oncogene 2005, 24:6185-6193.
45. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-1783.
46. Yoshino T., Shiina H., Urakami S., Kikuno N., Yoneda T., et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006, 12:6116-6124.
47. Yamanaka K., Rocchi P., Miyake H., Fazli L., Vessella B., et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005, 4:1689-1698.